Suppr超能文献

相似文献

1
Virus dynamics and drug therapy.
Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6971-6. doi: 10.1073/pnas.94.13.6971.
2
The review of differential equation models of HBV infection dynamics.
J Virol Methods. 2019 Apr;266:103-113. doi: 10.1016/j.jviromet.2019.01.014. Epub 2019 Feb 1.
3
Systems mapping of HIV-1 infection.
BMC Genet. 2012 Oct 23;13:91. doi: 10.1186/1471-2156-13-91.
5
Virus-Host Interactions: New Insights and Advances in Drug Development Against Viral Pathogens.
Curr Drug Metab. 2017;18(10):942-970. doi: 10.2174/1389200218666170925115132.
6
Population dynamics of immune responses to persistent viruses.
Science. 1996 Apr 5;272(5258):74-9. doi: 10.1126/science.272.5258.74.
7
Virus load and antigenic diversity.
Bull Math Biol. 1997 Sep;59(5):881-96. doi: 10.1007/BF02459997.
8
Viral fitness: definitions, measurement, and current insights.
Curr Opin Virol. 2012 Oct;2(5):538-45. doi: 10.1016/j.coviro.2012.07.007. Epub 2012 Sep 15.
10
Viral dynamics in hepatitis B virus infection.
Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4398-402. doi: 10.1073/pnas.93.9.4398.

引用本文的文献

1
Viral rebound and safety of nirmatrelvir/ritonavir for lung-transplant recipients infected with SARS-CoV-2.
Biosaf Health. 2023 Sep 2;5(5):266-271. doi: 10.1016/j.bsheal.2023.08.004. eCollection 2023 Oct.
2
Modeling dynamics of acute HIV infection incorporating density-dependent cell death and multiplicity of infection.
PLoS Comput Biol. 2024 Jun 7;20(6):e1012129. doi: 10.1371/journal.pcbi.1012129. eCollection 2024 Jun.
3
Modeling resistance to the broadly neutralizing antibody PGT121 in people living with HIV-1.
PLoS Comput Biol. 2024 Mar 29;20(3):e1011518. doi: 10.1371/journal.pcbi.1011518. eCollection 2024 Mar.
4
Dynamical modelling of viral infection and cooperative immune protection in COVID-19 patients.
PLoS Comput Biol. 2023 Sep 1;19(9):e1011383. doi: 10.1371/journal.pcbi.1011383. eCollection 2023 Sep.
5
Inhibition of Human Coronaviruses by Combinations of Host-Targeted and Direct-Acting Antivirals.
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0170322. doi: 10.1128/aac.01703-22. Epub 2023 Mar 28.
6
The risk of drug resistance during long-acting antimicrobial therapy.
Proc Biol Sci. 2022 Nov 9;289(1986):20221444. doi: 10.1098/rspb.2022.1444.
8
Molecular Communications in Viral Infections Research: Modeling, Experimental Data, and Future Directions.
IEEE Trans Mol Biol Multiscale Commun. 2021 Apr 15;7(3):121-141. doi: 10.1109/TMBMC.2021.3071780. eCollection 2021 Sep.
9
Forecasting emergence of COVID-19 variants of concern.
PLoS One. 2022 Feb 24;17(2):e0264198. doi: 10.1371/journal.pone.0264198. eCollection 2022.
10
Cross-scale dynamics and the evolutionary emergence of infectious diseases.
Virus Evol. 2021 Apr 20;7(1):veaa105. doi: 10.1093/ve/veaa105. eCollection 2021 Jan.

本文引用的文献

1
Decay characteristics of HIV-1-infected compartments during combination therapy.
Nature. 1997 May 8;387(6629):188-91. doi: 10.1038/387188a0.
2
Dynamic multidrug therapies for HIV: a control theoretic approach.
J Theor Biol. 1997 Mar 7;185(1):15-29. doi: 10.1006/jtbi.1996.0253.
3
Human immunodeficiency virus drug therapy and virus load.
J Virol. 1997 Apr;71(4):3275-8. doi: 10.1128/JVI.71.4.3275-3278.1997.
4
Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations.
J Theor Biol. 1997 Jan 21;184(2):203-17. doi: 10.1006/jtbi.1996.0307.
5
HIV-1: gambling on the evolution of drug resistance?
Nat Med. 1997 Mar;3(3):268-71. doi: 10.1038/nm0397-268.
6
Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection.
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1890-5. doi: 10.1073/pnas.94.5.1890.
10
Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection.
Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15323-8. doi: 10.1073/pnas.93.26.15323.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验